These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22218632)

  • 1. Chemoprevention of prostate cancer: myths and realities.
    Violette PD; Saad F
    J Am Board Fam Med; 2012; 25(1):111-9. PubMed ID: 22218632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
    Kramer BS; Hagerty KL; Justman S; Somerfield MR; Albertsen PC; Blot WJ; Carter HB; Costantino JP; Epstein JI; Godley PA; Harris RP; Wilt TJ; Wittes J; Zon R; Schellhammer P;
    J Urol; 2009 Apr; 181(4):1642-57. PubMed ID: 19249063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
    Kramer BS; Hagerty KL; Justman S; Somerfield MR; Albertsen PC; Blot WJ; Ballentine Carter H; Costantino JP; Epstein JI; Godley PA; Harris RP; Wilt TJ; Wittes J; Zon R; Schellhammer P; ;
    J Clin Oncol; 2009 Mar; 27(9):1502-16. PubMed ID: 19252137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].
    An C; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):582-6. PubMed ID: 22338147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of prostate cancer.
    Klein EA
    Annu Rev Med; 2006; 57():49-63. PubMed ID: 16409136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do alpha-reductase inhibitors prevent prostate cancer? 2008 practice guideline from the American society of clinical oncology and American urological association.
    Thüer D; Pfister D; Epplen R; Brehmer B; Heidenreich A
    Pol Arch Med Wewn; 2009 Oct; 119(10):648-53. PubMed ID: 19847141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III prostate cancer chemoprevention trials.
    Parnes HL; Brawley OW; Minasian LM; Ford LG
    Recent Results Cancer Res; 2014; 202():73-7. PubMed ID: 24531780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer prevention: concepts and clinical recommendations.
    Silberstein JL; Parsons JK
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):300-6. PubMed ID: 20567257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention in Prostate Cancer: Current Perspective and Future Directions.
    Rivero JR; Thompson IM; Liss MA; Kaushik D
    Cold Spring Harb Perspect Med; 2018 Oct; 8(10):. PubMed ID: 29311128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
    Hamilton RJ
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1259-1260. PubMed ID: 35775229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.
    Liss MA; Thompson IM
    Curr Opin Urol; 2018 Jan; 28(1):42-45. PubMed ID: 29095730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk adapted chemoprevention for prostate cancer: an option?
    Schmitz-Dräger BJ; Schöffski O; Marberger M; Sahin S; Schmid HP
    Recent Results Cancer Res; 2014; 202():79-91. PubMed ID: 24531781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Alpha-reductase inhibitors in diseases of the prostate.
    Carrasquillo RJ; Nealy SW; Wang DS
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):488-92. PubMed ID: 25268733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride: novel milestones in prostate cancer chemoprevention.
    Rove KO; Crawford ED
    Drugs Today (Barc); 2011 Feb; 47(2):135-44. PubMed ID: 21431101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
    Wilt TJ; Macdonald R; Hagerty K; Schellhammer P; Tacklind J; Somerfield MR; Kramer BS
    BJU Int; 2010 Nov; 106(10):1444-51. PubMed ID: 20977593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges.
    Earnshaw SR; Brogan AP; McDade CL
    Pharmacoeconomics; 2013 Apr; 31(4):289-304. PubMed ID: 23519744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer chemoprevention.
    Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
    Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.